Log in

NYSE:PKI - PerkinElmer Stock Price, Forecast & News

$84.32
-1.68 (-1.95 %)
(As of 02/28/2020 08:00 AM ET)
Today's Range
$83.63
Now: $84.32
$87.72
50-Day Range
$84.32
MA: $96.16
$101.73
52-Week Range
$78.35
Now: $84.32
$103.00
Volume1.02 million shs
Average Volume575,981 shs
Market Capitalization$9.37 billion
P/E Ratio41.33
Dividend Yield0.33%
Beta1.35
PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services. Read More…

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorComputer and Technology
CUSIP71404610
Phone781-663-6900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.88 billion
Cash Flow$6.15 per share
Book Value$25.33 per share

Profitability

Net Income$227.56 million

Miscellaneous

Employees12,500
Market Cap$9.37 billion
Next Earnings Date4/23/2020 (Estimated)
OptionableOptionable

Receive PKI News and Ratings via Email

Sign-up to receive the latest news and ratings for PKI and its competitors with MarketBeat's FREE daily newsletter.


PerkinElmer (NYSE:PKI) Frequently Asked Questions

What is PerkinElmer's stock symbol?

PerkinElmer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PKI."

How often does PerkinElmer pay dividends? What is the dividend yield for PerkinElmer?

PerkinElmer declared a quarterly dividend on Thursday, January 23rd. Investors of record on Friday, April 17th will be paid a dividend of $0.07 per share on Friday, May 8th. This represents a $0.28 dividend on an annualized basis and a yield of 0.33%. The ex-dividend date is Thursday, April 16th. View PerkinElmer's Dividend History.

How were PerkinElmer's earnings last quarter?

PerkinElmer, Inc. (NYSE:PKI) released its quarterly earnings results on Monday, January, 27th. The medical research company reported $1.35 earnings per share for the quarter, beating the Zacks' consensus estimate of $1.32 by $0.03. The medical research company earned $805.50 million during the quarter, compared to analyst estimates of $801.14 million. PerkinElmer had a net margin of 7.89% and a return on equity of 16.80%. The business's revenue was up 6.5% on a year-over-year basis. During the same quarter last year, the company earned $1.18 earnings per share. View PerkinElmer's Earnings History.

When is PerkinElmer's next earnings date?

PerkinElmer is scheduled to release their next quarterly earnings announcement on Thursday, April 23rd 2020. View Earnings Estimates for PerkinElmer.

What guidance has PerkinElmer issued on next quarter's earnings?

PerkinElmer updated its FY20 earnings guidance on Monday, January, 27th. The company provided EPS guidance of $4.50-4.60 for the period, compared to the Thomson Reuters consensus estimate of $4.63. The company issued revenue guidance of $3.05-3.09 billion, compared to the consensus revenue estimate of $3.08 billion.

What price target have analysts set for PKI?

13 Wall Street analysts have issued 1 year price objectives for PerkinElmer's stock. Their forecasts range from $41.00 to $115.00. On average, they expect PerkinElmer's share price to reach $85.08 in the next twelve months. This suggests a possible upside of 0.9% from the stock's current price. View Analyst Price Targets for PerkinElmer.

What is the consensus analysts' recommendation for PerkinElmer?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PerkinElmer in the last year. There are currently 8 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for PerkinElmer.

Has PerkinElmer been receiving favorable news coverage?

Media stories about PKI stock have trended extremely negative recently, according to InfoTrie. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. PerkinElmer earned a news sentiment score of -4.2 on InfoTrie's scale. They also gave headlines about the medical research company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for PerkinElmer.

Are investors shorting PerkinElmer?

PerkinElmer saw a decline in short interest in the month of February. As of February 14th, there was short interest totalling 4,950,000 shares, a decline of 13.3% from the January 30th total of 5,710,000 shares. Based on an average daily volume of 567,600 shares, the days-to-cover ratio is presently 8.7 days. Currently, 4.5% of the company's shares are short sold. View PerkinElmer's Current Options Chain.

Who are some of PerkinElmer's key competitors?

What other stocks do shareholders of PerkinElmer own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PerkinElmer investors own include NVIDIA (NVDA), AbbVie (ABBV), IBM (IBM), Visa (V), Alibaba Group (BABA), Thermo Fisher Scientific (TMO), Adobe (ADBE), Cisco Systems (CSCO), salesforce.com (CRM) and Home Depot (HD).

Who are PerkinElmer's key executives?

PerkinElmer's management team includes the folowing people:
  • Mr. Robert F. Friel, Chairman & CEO (Age 63)
  • Dr. Prahlad R. Singh, Pres & COO (Age 54)
  • Mr. James M. Mock, Sr. VP & CFO (Age 42)
  • Mr. Joel S. Goldberg, Sr. VP of Admin., Gen. Counsel & Sec. (Age 50)
  • Mr. James Corbett, Exec. VP and Pres of Discovery & Analytical Solutions (Age 56)

Who are PerkinElmer's major shareholders?

PerkinElmer's stock is owned by many different of retail and institutional investors. Top institutional investors include Capital Research Global Investors (10.67%), Janus Henderson Group PLC (5.88%), Massachusetts Financial Services Co. MA (4.46%), State Street Corp (3.99%), King Luther Capital Management Corp (2.27%) and Pictet Asset Management Ltd. (2.27%). Company insiders that own PerkinElmer stock include Alexis P Michas, Andrew Okun, Daniel R Tereau, Deborah A Butters, Frank Anders Wilson, James Corbett, Joel S Goldberg, Nicholas A Lopardo, Pascale Witz, Patrick J Sullivan, Peter Barrett, Prahlad R Singh and Robert F Friel. View Institutional Ownership Trends for PerkinElmer.

Which institutional investors are selling PerkinElmer stock?

PKI stock was sold by a variety of institutional investors in the last quarter, including Echo Street Capital Management LLC, First Trust Advisors LP, Williams Jones Wealth Management LLC., FMR LLC, Lord Abbett & CO. LLC, Nikko Asset Management Americas Inc., Artemis Investment Management LLP and Bank of America Corp DE. Company insiders that have sold PerkinElmer company stock in the last year include Alexis P Michas, Andrew Okun, Daniel R Tereau, Deborah A Butters, Joel S Goldberg, Pascale Witz and Prahlad R Singh. View Insider Buying and Selling for PerkinElmer.

Which institutional investors are buying PerkinElmer stock?

PKI stock was bought by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Massachusetts Financial Services Co. MA, KBC Group NV, Janus Henderson Group PLC, Pictet Asset Management Ltd., Alta Capital Management LLC, Cannell Peter B & Co. Inc. and State of Michigan Retirement System. View Insider Buying and Selling for PerkinElmer.

How do I buy shares of PerkinElmer?

Shares of PKI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is PerkinElmer's stock price today?

One share of PKI stock can currently be purchased for approximately $84.32.

How big of a company is PerkinElmer?

PerkinElmer has a market capitalization of $9.37 billion and generates $2.88 billion in revenue each year. The medical research company earns $227.56 million in net income (profit) each year or $4.10 on an earnings per share basis. PerkinElmer employs 12,500 workers across the globe.View Additional Information About PerkinElmer.

What is PerkinElmer's official website?

The official website for PerkinElmer is http://www.perkinelmer.com/.

How can I contact PerkinElmer?

PerkinElmer's mailing address is 940 WINTER STREET, WALTHAM MA, 02451. The medical research company can be reached via phone at 781-663-6900 or via email at [email protected]


MarketBeat Community Rating for PerkinElmer (NYSE PKI)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  464 (Vote Outperform)
Underperform Votes:  476 (Vote Underperform)
Total Votes:  940
MarketBeat's community ratings are surveys of what our community members think about PerkinElmer and other stocks. Vote "Outperform" if you believe PKI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PKI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel